Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: First Affiliated Hospital of Xinjiang Medical University
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05300152 |
NCT05300152 | N/A |
Completed |
Tooth, Nonvital|Root Resorption|Tooth Resorption |
2024-07-12 |
2024-11-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
ChiCTR2000029139 |
ChiCTR2000029139 | N/A |
Not yet recruiting |
Unknown |
2021-02-01 |
|||
ChiCTR2000029120 |
ChiCTR2000029120 | N/A |
Not yet recruiting |
Unknown |
2021-02-01 |
|||
NCT03820635 |
MVasCDN | N/A |
Unknown status |
Calcinosis|Vascular Calcification|Diabetic Nephropathy|Kidney Diseases |
2020-07-01 |
2021-01-06 |
||
NCT04274504 |
IRB 2019035 | N/A |
Completed |
Male Breast Cancer |
2019-10-01 |
2020-02-19 |
Primary Endpoints|Treatments |
|
NCT01909999 |
AJP2012 | N/A |
Completed |
Jaw, Edentulous |
2012-10-01 |
2019-03-19 |
Treatments |
|
NCT00970398 |
NCT00970398 | N/A |
Unknown status |
Other |
2012-09-01 |
2019-03-19 |
Treatments |
|
NCT02029105 |
NCT02029105 | N/A |
Completed |
Mesothelioma |
2010-12-01 |
2019-03-20 |
Treatments |